The growth is just getting started at Biogen Idec (NASDAQ: BIIB ) . OK, so it’s been ongoing for quite some time, but it certainly isn’t about to end anytime soon. The company recently launched Tecfidera for multiple sclerosis in the United States, completed three regulatory filings, is expecting three market launches in 2014, and has major trials releasing data […]
A doubling of Gilead Sciences ‘ sales has given investors plenty of reason to cheer on the biotech Goliath over the past year. However, with Gilead Sciences’ sales growth set to slow this year, investors may find that these three top biotech stocks prove to be a better bet in 2015.Source: Biogen Idec: Gilead Sciences’ slowing sales growth this year […]
Once again, deals and collaborations made news in the biotech sector with BioMarin (BMRN – Analyst Report) announcing its intention to acquire Prosensa (RNA – Snapshot Report) and Five Prime Therapeutics (FPRX – Snapshot Report) signing a second immuno-oncology focused deal with Bristol-Myers Squibb.Meanwhile, AbbVie (ABBV – Analyst Report) continues to progress with its hepatitis C virus (HCV) treatment with […]
Why Has Biogen (BIIB) Stock Been Trading Down?
Biogen stock has been falling due to patent issues and negative sentiments regarding the death of a patient who had been using Tecfidera. However, the company’s pipeline drugs show potential
Published: November 21, 2014 at 2:19 pm ESTBy: Hannah IshmaelPage 1 of 2
Click Ticker to See live coverageBIIB
FWP
NVS
Biogen Idec Inc (NASDAQ:BIIB) stock has been […]
It was all about earnings last week with several biotech companies reporting third quarter results. While it was a “beat and raise” quarter for quite a few companies, some companies narrowed their outlooks for the year.Recap of the Week’s Most Important Stories1. Companies like Celgene (CELG – Analyst Report), Biogen (BIIB – Analyst Report), Alexion (ALXN – Analyst Report), Cubist […]
It was all about earnings last week with several biotech companies reporting third quarter results. While it was a “beat and raise” quarter for quite a few companies, some companies narrowed their outlooks for the year.Recap of the Week’s Most Important Stories1. Companies like Celgene (CELG – Analyst Report), Biogen (BIIB – Analyst Report), Alexion (ALXN – Analyst Report), Cubist […]
